printemailclick to share buttonfacebooktwitterlinkedin
Lung Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)
 

The Lung Cancer Disease Site Group (Lung Cancer DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance. The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC (ccopgi@mcmaster.ca) or the lead author of the document.

Non-Small Cell Lung Cancer

  • Treatment of Patients with Stage III (N2 or N3) Non-Small Cell Lung Cancer
    Guideline 7-3 Version 3
    Status: CURRENT: September 2017
  • Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
    Guideline 7-A-2016-3
    Status: CURRENT
    This clinical practice guideline is an ASCO-CCO collaboration, produced by a joint expert panel convened by the ASCO Clinical Practice Guidelines Committee and the CCO Program In Evidence-based Care
  • Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer
    Guideline 7-10 Version 3 : November 2016
    Status: CURRENT
  • Radiotherapy with Curative Intent in Patients with Early Stage, Medically Inoperative, Non-Small Cell Lung Cancer
    Guideline 7-21: May, 2016
    Status: CURRENT
  • The Use of Systemic Treatment in the Maintenance of Patients with Non-small Cell Lung Cancer
    Guideline 7-22 : August 2015
    Status: CURRENT
  • Use of the Epidermal Growth Factor Receptor Inhibitors, Gefitinib (Iressa®) Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icontinib in the Treatment of Non-small Cell Lung Cancer: A Clinical Practice Guideline
    7-9 Version 2 EBS: May 2014
    Status: CURRENT
  • Positron Emission Tomography in Radiation Treatment Planning for Lung Cancer
    7-18 EBS: November 2010
    Status: CURRENT
  • Management of Unresected Stage III Non-Small Cell Lung Cancer
    7-3 EBS Version 2.2005: January 2006 Update
    Status: IN REVIEW
  • Use of Preoperative Chemotherapy with or without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer
    7-4 Version 2 PG: May 16, 2013
    Status: IN REVIEW 
  • The Role of Photodynamic Therapy (PDT) in Patients with Non-Small Cell Lung Cancer
    7-15 EBS Version 2: December 2013 
    Status: CURRENT
  • The Role of High Dose Rate Brachytherapy in the Palliation of Patients with Non-small Cell Lung Cancer
    7-16 Version 2 EBS: May 2013
    Status: IN REVIEW

Small Cell Lung Cancer

  • The Role of Combination Chemotherapy in the Initial Management of Limited-Stage Small-Cell Lung Cancer
    7-13-1 Version 2 EBS: October 2012
    Status: IN REVIEW
  • Chemotherapy for Relapsed Small Cell Lung Cancer
    7-17 Version 2 EBS: May 2013
    Status: CURRENT

Non-Small Cell and Small Cell Lung Cancer

  • 18-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer
    7-20 Version 2 EBS: October 2012
    Status: CURRENT

Mesothelioma

  • The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma
    7-14-1 EBS Version 2: November 2012
    Status: CURRENT
  • Surgical Management of Malignant Pleural Mesothelioma
    7-14-2 EBS: May 2012
    Status: CURRENT

Thymoma




For Education and Information Purposes

  • Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer 
  • Postoperative Adjuvant Chemotherapy in Completely Resected Non-Small Cell Lung Cancer: Guidance for Nurses
  • Second line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer
  • The Role of Radiation Therapy in Malignant Pleural Mesothelioma
  • Prophylactic Cranial Irradiation in Small Cell Lung Cancer
  • The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
  • Systematic Review: “Reprinted from The Annals of Thoracic Surgery, Vol 81, Alam N, Darling G, Shepherd FA, Mackay JA, Evans WK, and the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, Postoperative chemotherapy in non-small cell lung cancer: a systematic review, Pages No. 1926-36, Copyright 2006, with permission from the Society of Thoracic Surgeons. All rights reserved.”

  • Chemotherapy in Stage IV (Metastatic) Non-Small Cell Lung Cancer
    7-2 EBS: November 2009
    Status: ARCHIVED
    This document has been retired and incorporated into 7-10 v2.2010 EBS: The Role of First-Line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.
  • Use of Vinorelbine in Non-Small Cell Lung Cancer
    7-5 EBS: November 2009
    Status: ARCHIVED
    This document has been retired and incorporated into 7-10 v2.2010 EBS: The Role of First-Line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.
  • The Role of Taxanes in First-line Therapy for Advanced Non-Small Cell Lung Cancer
    7-7-1 EBS: November 2009
    Status: ARCHIVED
    This document has been retired and incorporated into 7-10 v2.2010 EBS: The Role of First-Line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.
  • The Role of Single-Agent Docetaxel (Taxotere®) as a Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    7-7-2 PG : March 2006
    Status: ARCHIVED
    This document has been retired and incorporated in 7-19 EBS: Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer.
  • Use of Gemcitabine in Non-Small Cell Lung Cancer
    7-8 EBS: November 2009
    Status: ARCHIVED
    This document has been retired and incorporated into 7-10 EBS v2.2010: The Role of First-Line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.


    Contact:
    Program in Evidence-Based Care (PEBC)
    McMaster University, Juravinski Site
    G Wing, 2nd Floor
    711 Concession Street
    Hamilton, Ontario, Canada
    L8V 1C3

    Phone: 905.527.4322 ext. 42822
    Fax: 905.526.6775
    Email: ccopgi@mcmaster.ca




Last modified: Fri, Sep 15, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo